BOTHELL, Wash., April 16, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, President and co-CEO, will present a Company overview at the Life Science Innovation Northwest (LSINW) 2025 Conference on Wednesday, April 23, 2025 at 3:00 p.m. Pacific time. The conference is being held April 23-24 at the Seattle Convention Center.
About Life Science Innovation Northwest
Life Science Innovation Northwest (LSINW) is the Pacific Northwest’s largest annual life science conference. This event brings together investors, public and private life science organizations, research institutions, scientists, entrepreneurs, and the global health community to discuss and feature some of the most compelling life science breakthroughs of our time. Bringing together over 700 attendees, LSINW features 80+ company and research institution presentations, keynote addresses from industry leaders, engaging panel discussions on emerging trends, a dynamic startup fast pitch showdown, insightful poster presentations, and more - making it the must-attend event for the PNW’s life science community. More information is available here.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.31 |
Daily Volume: | 1,245 |
Market Cap: | US$13.320M |
March 31, 2025 December 31, 2024 November 13, 2024 September 26, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load